- Poster presentation
- Open Access
Thrombopenia and/or splenomegaly in HIV/HCV co-infected patients with mild liver fibrosis alerts for the risk of portal hepatopathy
© Vispo et al; licensee BioMed Central Ltd. 2008
- Published: 10 November 2008
- Portal Hypertension
- Liver Fibrosis
- Variceal Bleeding
- Advanced Liver Fibrosis
Non-cirrhotic portal hypertension has recently emerged as a new entity in HIV-infected patients. Histological findings often reveal different hepatic portal perivascular abnormalities. In most cases it was related to previous didanosine exposure. Although its recognition could be more difficult, this drug-induced vascular damage in the liver might also appear in HIV/HCV co-infected patients.
Prior didanosine exposure (months)
CD4 count (cells/mm3)
Plasma HIV-RNA (copies/ml)
Liver fibrosis stage (Metavir, stiffness KPa)
Primary hepatic vascular damage induced by didanosine might result in non-cirrhotic portal hypertension. This condition may appear in HIV patients without any known cause of liver disease, as well as superimposed to other hepatic illnesses, as chronic hepatitis C. The recognition of clinical classical signs of portal hypertension (e.g. thrombopenia, splenomegaly) in the absence of a significant liver fibrosis or synthetic function compromise may alert to the possibility of this condition.
This article is published under license to BioMed Central Ltd.